INTRODUCTION {#s1}
============

Obesity and diabetes are considered as important risk factors of cancers. According to a population-based study in 2012, a quarter of the cancer cases possess high body-mass index (BMI) \[[@R1]\]. Among them, prostate, breast, colorectal, thyroid, renal, endometrial, pancreatic and esophageal cancers are identified as obesity-related cancers by a number of epidemiological studies and meta-analyses \[[@R2]\]. Also, individuals with diabetes have significant higher risk of cancer compared with no diabetes \[[@R3]\]. However, the mechanisms underlying the association between obesity or diabetes and cancer development are currently not fully elucidated.

Resistin was first identified by a screening of adipocyte products that were decreased by rosiglitazone in mice. It was considered as the potential link between obesity and diabetes \[[@R4]\]. Resistin expression in prostate epithelial cells was also found to be higher in patients with prostate cancer, compared with that in those with benign prostate hyperplasia \[[@R5]\]. Additionally, serum resistin levels were reported to be increased in several cancers, such as breast and colorectal cancers. Studies revealed resistin could promote the proliferation, angiogenesis, and metastasis of cancer cells by stimulating specific signaling pathways including p38 MAPK/NF-kB and PI3K/Akt \[[@R6]--[@R8]\]. Although many studies provided evidence that high resistin levels were associated with the risk of obesity-associated malignancies, some studies observed different results. Many studies showed resistin levels were similar, even lower in cancer patients compare with normal controls. The reasons underlying these heterogeneous findings need to be investigated.

To the best of our knowledge, no systematic review evaluated the association of blood resistin levels with obesity-related cancer risk. More convincing evidence is needed to reveal the role of resistin in obesity-related cancers. The present study aimed to evaluate the association of circulating resistin levels with the risk of obesity-related cancers by conducting a meta-analysis.

RESULTS {#s2}
=======

Literature search {#s2_1}
-----------------

The procedure of literature selection is presented in Figure [1](#F1){ref-type="fig"}. We identified 42 potentially relevant papers concerning resistin in relation to cancer risk. 9 papers were excluded because circulating resistin levels were not measured in serum or plasma of the healthy controls or obesity-related cancers. 12 papers were excluded because that they did not provide sufficient information. Finally, for pooling odds ratios (ORs) analysis, 13 articles were included involving 9 retrospective studies and 4 prospective studies \[[@R9]--[@R21]\]. With regard to the pooling measures on standardized mean difference (SMD), 17 papers containing 14 retrospective articles and 3 prospective articles \[[@R9]--[@R14], [@R19]--[@R29]\] were included.

![Procedure of article selection](oncotarget-07-57694-g001){#F1}

Characteristics of included studies {#s2_2}
-----------------------------------

13 studies for meta-analysis performed on ORs were published from 2007 to 2016, involving 2756 cases and 3350 controls. 8 and 4 articles focused on breast and colorectal cancer, respectively \[[@R9]--[@R20]\]. 6 articles were conducted in Asia \[[@R9], [@R13]--[@R17]\], 3 in Europe \[[@R11], [@R12], [@R21]\], 3 in the USA \[[@R18]--[@R20]\], and 1 in Africa \[[@R10]\]. The ORs of most studies were adjusted for age and BMI. Circulating resistin levels were measured by enzyme-linked immunosorbent assay (ELISA) in 10 studies \[[@R9]--[@R17], [@R21]\], and by Human Adipokine Panel in 3 studies \[[@R18]--[@R20]\]. The quality score of studies ranged from 5 stars to 8 stars according to the 9-star Newcastal-Ottawa Scale \[[@R30]\]. General characteristics of the involved studies are shown in Table [1](#T1){ref-type="table"}.

###### Characteristics of studies included in pooling ORs analysis

  Author                                     Year   Country         Cancer Type   Control Source   Study Design                    Detection Assay         NOS Score   Case/Control   Adjusted OR (95% CI)   Adjustments
  ------------------------------------------ ------ --------------- ------------- ---------------- ------------------------------- ----------------------- ----------- -------------- ---------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Alokail                                    2013   Saudi Arabia    BC            HB               Retrospective case-control      ELISA                   6           56/53          1.90 (0.62-5.70)       age, menopausal status of menarche
  Aly                                        2013   Egypt           BC            HB               Retrospective case-control      ELISA                   5           35/40          1.26(1.21-1.93)        No
  Dalamaga                                   2013   Greece          BC            HB               Retrospective case-control      ELISA                   6           102/102        1.17(1.03-1.34)        age, date of diagnosis, education, BMI, waist circumference, family history of cancer, use of exogenous hormones, smoking history, adiponectin and leptin concentration, inflammatory markers, alcohol consumption, smoking status
  Danese                                     2012   Italy           CC            HB               Retrospective case-control      ELISA                   6           40/40          1.33(1.03-1.72)        age, sex, BMI, lifestyle parameters
  Gaudet[1](#tfn_001){ref-type="table-fn"}   2010   United States   BC            PB               Prospective nest case-control   Human Adipokine Panel   7           234/231        1.09(0.58-2.08)        age, BMI, number of births, age at first full-term birth, age at menopause, and current postmenopausal hormone use
  Gunter[1](#tfn_001){ref-type="table-fn"}   2015   United States   BC            PB               Prospective case-cohort         Human Adipokine Panel   6           875/820        1.00(0.81-1.22)        age, ethnicity, alcohol consumption, family history of breast cancer, parity, year of menstrual cycling, age at first child\'s birth, use of hormone therapy, endogenous estradiol levels, history of benign breast disease, BMI and physical activity
  Ho[1](#tfn_001){ref-type="table-fn"}       2012   United States   CC            PB               Prospective case-cohort         Human Adipokine Panel   6           427/797        0.89(0.58-1.38)        age, race, smoking status, ever had colonoscopy, estrogen level, insulin, waist circumference
  Hou                                        2007   China           BC            HB               Retrospective case-control      ELISA                   6           80/50          1.34(1.11-2.35)        NA
  Kang                                       2007   Korea           BC            HB               Retrospective case-control      ELISA                   6           41/43          2.77(1.40-5.50)        age, BMI, status of menopause, serum glucose and adiponectin
  Liao[1](#tfn_001){ref-type="table-fn"}     2012   Finland         RCC           PB               Prospective nest case-control   ELISA                   8           273/273        1.15(0.80-1.51)        number of years smoking, presence of hypertension, history of diabetes and physical activity
  Nakajima                                   2010   Japan           CC            HB               Retrospective case-control      ELISA                   7           115/115        2.07(1.05-4.06)        NA
  Otake                                      2010   Japan           CC            HB               Retrospective case-control      ELISA                   5           98/26          0.88(0.16-1.60)        No
  Sun[1](#tfn_001){ref-type="table-fn"}      2010   Taiwan          BC            HB               Retrospective case-control      ELISA                   7           380/760        1.77(0.90-2.64)        age, waist circumference, hormone replacement therapy use, family history of breast cancer, age at enrollment, age at menarche, age at first full-term pregnancy, parity number

Risk estimates were recalculated by the method proposed by Harmling et al.

Abbreviations: HB= Hospital Based; PB = Population Based; OR = Odds Ratio; CI = Confidence Interval; ELISA = Enzyme-linked Immunosorbent Assay; BMI = Body Mass Index; NA = Unknown; NOS = Newcastle-Ottawa Scale; BC = Breast Cancer; CC = Colorectal Cancer; RCC = Renal Cell Cancer.

For pooling SMD analysis, 17 articles constituted 2421 cases and 2731 controls. Because 1 article consisted of 2 studies \[[@R24]\], a total of 18 studies were included. 8 studies were conducted in Asia \[[@R9], [@R13], [@R14], [@R22], [@R23], [@R26], [@R27], [@R29]\], 7 in Europe \[[@R11], [@R12], [@R21], [@R24], [@R25], [@R28]\], and 2 in the USA \[[@R19], [@R20]\]. 9 and 7 studies focused on breast and colorectal cancers, respectively \[[@R9]--[@R14], [@R19], [@R20], [@R22]--[@R24], [@R26]--[@R29]\] (Table [2](#T2){ref-type="table"}).

###### Characteristics of studies included in pooling SMD analysis

  Author                                            Year   Country         Cancer Type   Study Design                    Detection Assay                   NOS Score   Cases   Controls                         
  ------------------------------------------------- ------ --------------- ------------- ------------------------------- --------------------------------- ----------- ------- ---------- ------- ----- ------- ------
  Al-Haritby                                        2010   Saudi Arabia    CC            Retrospective case-control      ELISA                             4           60      19.44      8.46    60    5.45    2.73
  Alokail                                           2013   Saudi Arabia    BC            Retrospective case-control      ELISA                             6           56      18.9       1.2     53    15.2    1
  Aly                                               2013   Egypt           BC            Retrospective case-control      ELISA                             6           35      4.42       4.74    40    1.84    2.35
  Assiri                                            2015   Saudi Arabia    BC            Retrospective case-control      ELISA                             6           82      26.24      1.59    68    22.69   2.58
  Crusistomo(a)[1](#tfn_002){ref-type="table-fn"}   2016   Portugal        BC            Retrospective case-control      ELISA                             7           30      11.6       7.31    29    7.51    3.6
  Crusistomo(b)[1](#tfn_002){ref-type="table-fn"}   2016   Portugal        BC            Retrospective case-control      ELISA                             7           47      16.1       10.37   48    10.4    9.75
  Dalamaga                                          2013   Greece          BC            Retrospective case-control      ELISA                             6           102     11.2       6.4     102   7.7     4.85
  Danese[1](#tfn_002){ref-type="table-fn"}          2012   Italy           CC            Retrospective case-control      ELISA                             6           40      8.96       3.42    40    4.97    1.07
  Diakowska                                         2014   Poland          EC            Retrospective case-control      ELISA                             6           41      8.99       3.21    60    7.5     2.7
  Gonullu[1](#tfn_002){ref-type="table-fn"}         2009   Turkey          CC            Retrospective case-control      ELISA                             5           36      6.1        3.3     37    4.5     1.5
  Gunter[1](#tfn_002){ref-type="table-fn"}          2015   United States   BC            Prospective case-cohort         Milliplex Human Adipokine Panel   5           875     12.1       4       821   12.3    4.3
  Ho[1](#tfn_002){ref-type="table-fn"}              2012   United States   CC            Prospective case-cohort         Milliplex Human Adipokine Panel   6           457     12.8       4.81    834   12.3    4.3
  Hou                                               2007   China           BC            Retrospective case-control      ELISA                             6           80      26.35      5.36    50    23.32   4.75
  Joshi                                             2014   Korea           CC            Retrospective case-control      ELISA                             6           100     4.9        2.3     100   2.8     1.7
  Kang                                              2007   Korea           BC            Retrospective case-control      ELISA                             6           41      5.23       6.9     43    1.46    2
  Kumor                                             2008   Poland          CC            Retrospective case-control      ELISA                             4           36      6.79       2.41    25    3.6     1.08
  Liao[1](#tfn_002){ref-type="table-fn"}            2012   Finland         RCC           Prospective nest case-control   ELISA                             8           273     9.27       2.73    273   9.28    2.83
  Tulubas                                           2014   Turkey          CC            Retrospective case-control      ELISA                             6           30      18.77      5.09    30    13.36   6.36

Data was recalculated by the method proposed by Hozo et al.

Abbreviations: SD = Standard Deviation; CI = Confidence Interval; ELISA = Enzyme-linked Immunosorbent Assay; NOS = Newcastle-Ottawa Scale; CI = Confidence Interval; BC = Breast Cancer; CC = Colorectal Cancer; EC = Esophageal Cancer

Pooling of studies and subgroup analysis {#s2_3}
----------------------------------------

The multivariate adjusted ORs for each study and the combined OR are present in Figure [2a](#F2){ref-type="fig"}. The combined OR for cancer risk was 1.20 (95% CI = 1.10-1.30). There was no significant heterogeneity across the studies (*I*^2^ = 31.2%, *P* = 0.133). So a fixed-effects model was adopted (Figure [2a](#F2){ref-type="fig"}). Further, subgroup analysis by sample size, cancer type, geographic area, detection assay, study design, study quality, and BMI-match was conducted. High resistin levels were found to be associated with increased cancer risk in the studies of breast cancer (OR = 1.19, 95% CI = 1.08-1.31), colorectal cancer (OR = 1.25, 95% CI = 1.02-1.53), Asia (OR = 1.66, 95% CI = 1.29-2.13), Europe (OR = 1.20, 95% CI = 1.07-1.33), ELISA (OR = 1.26, 95% CI = 1.15-1.38), retrospective studies (OR = 1.27, 95% CI = 1.15-1.40). However, circulating resistin levels were similar between cases and controls in the studies of Human Adipokine Panel (OR = 0.99, 95% CI = 0.83-1.18), the USA (OR = 0.99, 95% CI = 0.83-1.18), and prospective studies (OR = 1.02, 95% CI = 0.88-1.20) (Table [3](#T3){ref-type="table"}).

###### Subgroup analysis of pooling ORs of circulating resistin and cancer risk

  Subgroup                No.   Fixed Effects OR(95%CI)   *I*^2^ (%)   *P* Value[^a^](#tfn_003){ref-type="table-fn"}   *P* Value[^b^](#tfn_004){ref-type="table-fn"}
  ----------------------- ----- ------------------------- ------------ ----------------------------------------------- -----------------------------------------------
  Total                   13    1.20(1.10,1.30)           31.2         0.133                                           
  Sample Size                                                          0.122                                           
  \<200                   6     1.35(1.16,1.57)           8.2          0.364                                           
  ≥200                    7     1.14(1.03,1.25)           29.0         0.207                                           
  Cancer Type                                                          0.829                                           
  Breast Cancer           8     1.19(1.08,1.31)           42.3         0.096                                           
  Colorectal Cancer       4     1.25(1.02,1.53)           40.9         0.166                                           
  Others                  1     1.15(0.80,1,51)                                                                        
  Geographic Area                                                      0.019                                           
  Asia                    6     1.66(1.29,2.13)           4.6          0.387                                           
  Europe                  3     1.20(1.07,1.33)           0.0          0.662                                           
  USA                     3     0.99(0.83,1.18)           0.0          0.849                                           
  Africa                  1     1.26(1.21,1.93)                                                                        
  Detection Assay                                                                                                      0.041
  ELISA                   10    1.26(1.15,1.38)           21.3         0.247                                           
  Human Adipokine Panel   3     0.99(0.83,1.18)           0.0          0.849                                           
  Study Design                                                         0.044                                           
  Retrospective Study     9     1.27(1.15,1.40)           27.9         0.197                                           
  Prospective Study       4     1.02(0.88,1.20)           0.0          0.800                                           
  Study quality                                                        0.490                                           
  NOS score(7-9)          4     1.32(1.04,1.69)           24.9         0.262                                           
  NOS score(5-6)          9     1.18(1.08,1.29)           36.9         0.123                                           
  BMI match                                                            0.340                                           
  Yes                     9     1.23(1.09,1.39)           46.0         0.063                                           
  No                      4     1.17(1.04,1.30)           0.0          0.534                                           

*P*-Value for heterogeneity within each subgroup.

*P*-Value for heterogeneity between subgroups with meta-regression analysis

Abbreviations: No. = Number of studies; ELISA = Enzyme-linked Immunosorbent Assay; NOS = Newcastle-Ottawa Scale; OR = Odds Ratio; CI = Confidence Interval; BMI = Body Mass Index

18 studies were available to evaluate the SMD of circulating resistin levels with obesity-related cancer risk. Because of high heterogeneity (*I^2^* = 95.7%, *P* = 0.000), a random-effects model was used. Higher resistin levels were present in cancer patients (SMD = 0.94, 95% CI = 0.63-1.25) (Figure [2b](#F2){ref-type="fig"}). Stratification analysis found that there was no significant association between circulating resistin levels and obesity-related cancer risk in prospective studies (SMD = 0.02, 95% CI = −0.09-0.12) (Figure [2b](#F2){ref-type="fig"}). However, for retrospective studies, stratification analysis showed that resistin levels were always higher in cancer patients (Table [4](#T4){ref-type="table"}).

###### Subgroup analysis of pooling SMD of circulating resistin levels and obesity-related cancer risk in retrospective studies

  Subgroup                      Number of studies   Random-Effects SMD(95% CI)   Heterogeneity   
  ----------------------------- ------------------- ---------------------------- --------------- -------
  Total                         15                  1.15(0.80,149)               90.0            0.000
  Sample Size                                                                                    
  \<100                         8                   0.91(0.64,1.19)              61.0            0.012
  ≥100                          7                   1.41(0.79,2.02)              94.9            0.000
  Cancer Type                                                                                    
  Breast Cancer                 8                   1.10(0.57,1.64)              92.6            0.000
  Colorectal Cancer             6                   1.33(0.87,1.79)              80.1            0.000
  Others                        1                   0.51(0.11,0.91)                              
  Geographic Area                                                                                
  Asia                          8                   1.39(0.82,1.95)              93.0            0.000
  Europe                        6                   0.89(0.53,1.26)              76.6            0.001
  Africa                        1                   0.70(0.24,1.17)                              
  Study Quality                                                                                  
  NOS Score(7-9)                3                   1.00(0.24,1.75)              89.0            0.000
  NOS Score(5-6)                10                  1.04(0.64,1.45)              89.7            0.000
  NOS Score(0-4)                2                   1.95(1.35,2.55)              61.8            0.106
  Resistin Levels in Controls                                                                    
  0-5 ng/ml                     6                   1.03(0.72,1.34)              65.3            0.013
  5-10ng/ml                     4                   1.01(0.27,1.75)              92.6            0.000
  10-15ng/ml                    2                   0.71(0.36,1.07)              15.0            0.278
  15- ng/ml                     3                   1.86(0.47,3.24)              96.9            0.000
  BMI Match                                                                                      
  Yes                           10                  1.40(0.90,1.91)              91.0            0.000
  No                            5                   0.70(0.50,0.90)              39.9            0.150

Abbreviations: NOS = Newcastle-Ottawa Scale; SMD = Standardized Mean Difference; CI = Confidence Interval; BMI = Body Mass Index

![The effect of circulating resistin levels on obesity-related cancer risk in pooling ORs (a) and SMD (b) analysis](oncotarget-07-57694-g002){#F2}

Heterogeneity analysis {#s2_4}
----------------------

Sensitivity analysis was conducted to test the robustness of the results of meta-analysis by omitting one study every time. Results showed remaining studies yielded consistent results in pooling both ORs and SMD analysis ([Figure S1](#SD1){ref-type="supplementary-material"}). Galbraith plot analysis was used to spot the outliners as the potential sources of heterogeneity. For the pooling ORs analysis, one study was identified as the outlier and possible major source of heterogeneity \[[@R14]\] (Figure [3a](#F3){ref-type="fig"}). Except for the study, the association between resistin levels and cancer risk was still significant (OR = 1.18, 95% CI = 1.09-1.28, *I^2^* = 5.0%, *P* (for heterogeneity analysis) = 0.396) ([Figure S2](#SD1){ref-type="supplementary-material"}a). For the pooling SMD analysis of retrospective studies, three studies were identified as major contributors to high heterogeneity \[[@R9], [@R12], [@R22], [@R23]\] (Figure [3b](#F3){ref-type="fig"}). After excluding those studies, high resistin levels were still found in cancer patients (SMD = 0.75, 95% CI = 0.63-0.87, *I^2^* = 39.3%, *P* (for heterogeneity analysis) = 0.087) ([Figure S2b](#SD1){ref-type="supplementary-material"}). Furthermore, exploratory univariate meta-regression analysis was performed with sample size, cancer type, geographic area, detection assay, study design, study quality, and BMI-match as the covariates. For pooling ORs analysis, geographic area (*P* = 0.019, adjusted R^2^ = 50.02%), detection assay (*P* = 0.041, adjusted R^2^ = 86.15%), and study design (*P* = 0.044, adjusted R^2^ = 13.31%) were found to be significant factors (Table [3](#T3){ref-type="table"}). For pooling SMD analysis of retrospective studies, meta-regression analysis revealed geographic area, BMI-match, size, and quality score could account for 66.7% between-study variance (tau2 from 0.547 to 0.182).

![Galbraith plots of the association between circulating resistin levels and obesity-related cancer risk in pooling ORs analysis (a) and pooling SMD analysis of retrospective studies (b)](oncotarget-07-57694-g003){#F3}

Estimation of publication bias {#s2_5}
------------------------------

Publication bias was examined by visual inspection of funnel plots and Egger\'s regression asymmetry test. For pooling ORs analysis, the shape of funnel plots did not indicate any evidence of publication bias (Figure [4a](#F4){ref-type="fig"}). Egger\'s regression test further confirmed this (*P* = 0.180) (Figure [4c](#F4){ref-type="fig"}). For pooling SMD analysis, the funnel plot had an asymmetrical distribution ([Figure S3a](#SD1){ref-type="supplementary-material"}). Egger\'s regression test also showed there was publication bias (*P* = 0.001) ([Figure S3b](#SD1){ref-type="supplementary-material"}). For pooling SMD analysis of retrospective studies, funnel plots had a slightly asymmetrical distribution (Figure [4b](#F4){ref-type="fig"}). However, Egger\'s regression test suggested publication bias was insignificant (*P* = 0.150) (Figure [4d](#F4){ref-type="fig"}).

![The funnel plots and Egger\'s bias plot of publication bias in pooling ORs analysis (a and c) and pooling SMD analysis of retrospective studies (b and d)](oncotarget-07-57694-g004){#F4}

DISCUSSION {#s3}
==========

Currently, increased attention has been paid to the role of resistin in obesity-related cancers. Whether circulating resistin levels are higher in cancer patients is inconsistent. A meta-analysis was conducted by pooling both ORs and SMD. Higher resistin levels were found to be associated with increased obesity-related cancer risk. Serum resistin levels may be an independent risk of obesity-related cancers, but not a predictor. It may be the first attempt to synthesize the existing studies to evaluate the association of circulating resistin levels with obesity-related cancer risk.

It is widely accepted that increased BMI and insulin resistance are associated with increased obesity-related cancer risk. Resistin was considered as an adipocytokine secreted by adipocytes, monocytes and macrophages, especially in the visceral adipose tissue. Increasing evidence has shown human resistin could stimulate the production of pro-inflammatory cytokines and was an inflammatory biomarker \[[@R31], [@R32]\]. Chronic inflammation plays an important role in tumorigenesis. It seems plausible that resistin levels may be associated with the incidence of obesity-related cancer. However, the results of clinical trials are not always consistent. Meta-analysis allows a much greater possibility of reaching reasonably strong conclusions. The results of our meta-analysis suggested circulating resistin levels were higher in obesity-related cancer patients and an independent risk factor of obesity-related cancers. For pooling ORs analysis, stratification analysis showed significance only in those studies with colorectal cancer, breast cancer, ELISA detection assay, Asia and Europe, and retrospective studies. There was a lack of strong association in the studies of Human Adipokine Panel detection assay, the USA, and prospective studies. For the pooling SMD analysis, the association was also insignificant only in prospective studies. The prospective studies were mostly conducted in the USA, and detected by Human Adipokine Panel, while most of the retrospective studies were performed in Asia and Europe, and used ELISA to detect serum or plasma resistin levels. For prospective studies, the blood for resistin detection was drawn at the baseline of the follow-up. At that time, all subjects including those becoming cases later were still free of cancer. For retrospective studies, blood was collected when patients were diagnosed with cancer. This may contribute greatly to the differences of results between retrospective studies and prospective studies. It indicates circulating resistin levels may not be a predictor of obesity-related cancers at least in the USA. Prospective studies need to be conducted in Asia and Europe, and retrospective studies need to be conducted in the USA.

The heterogeneity of between-study is common in meta-analysis. Meta-analysis showed significant between-study heterogeneity, especially in pooling SMD analysis. Sensitivity analysis, subgroup analysis, Galbraith plots, and meta-regression analysis were used to explore the potential causes of between-study heterogeneity and to reduce the heterogeneity. Sensitivity analysis didn\'t find any single study affected the estimated significance of pooled ORs or SMD. Galbraith plots indicated that 1 outlier study contributed to heterogeneity in pooling ORs analysis, while 4 outlier studies contributed to heterogeneity in pooling SMD analysis of retrospective studies. The results of the outlier studies greatly deviated from the pooling results. After omitting these studies, heterogeneity was insignificant. The pooling results didn\'t change significantly because of excluding the outlier studies. Meta-regression analysis found factors such as geographic area, detection assay, or study design almost completely accounted for some between-study variance in pooling ORs analysis, while geographic area, BMI-match, size, and quality score contributed significantly to heterogeneity of between-study in pooling SMD analysis of retrospective studies.

However, some limitations in the meta-analysis should be demonstrated, and the results should be prudently explained. First, our meta-analysis was limited to articles published in English. Slight publication bias may exist, especially for pooling SMD analysis. Some eligible articles may have been missed. Second, most studies included in our meta-analysis were case-control studies. It\'s widely known that case-control studies have inherent limits, such as selection bias, admission rate bias, detection signal bias. Third, the confounding factors in the studies for ORs analysis were inadequately considered due to various adjustments made in studies and some potential confounders were not considered in the majority of studies, such as diseases other than cancer, inflammatory conditions, drugs, and hormonal factors. Additionally, it should be noted that remarkable heterogeneity existed in pooling SMD analysis, and may have reduced the reliability of the meta-analysis.

In conclusion, this meta-analysis suggests circulating resistin levels may be higher in obesity-related cancer patients than in normal controls, and an independent biomarker of obesity-related cancer risk. But it may not be a predictor of obesity-related cancer risk. Given the limited number of studies included as well as the significant heterogeneity, more randomized and large-scale clinical trials, carefully controlled for potential confounding factors, are needed to confirm this association between resistin levels and obesity-related cancer risk in the future.

MATERIALS AND METHODS {#s4}
=====================

Search strategy {#s4_1}
---------------

A comprehensive literature screening was conducted for publications up to February 20th, 2016 from the following databases: (1) Pubmed (http://www.ncbi.nlm.nih.gov/pubmed/); (2) Embase (https://www.embase.com/); (3) Cochrane (http://www.cochranelibrary.com/). Search terms: "resistin, RETN", "cancer, tumor, neoplasm, carcinoma" and "serum, plasma, circulating, blood" were used in combination to retrieve the relevant literatures. Only papers written in English language were considered in this study. In addition, reference lists of articles were scrutinized to identify additional articles. This study was planned and conducted in accordance with standards of quality for reporting meta-analysis \[[@R33]\].

Eligibility criteria {#s4_2}
--------------------

Only studies meeting the following criteria were included: (1) the study must be an original epidemiological study; (2) the exposure of interest must be the serum or plasma resistin detected in blood samples; (3) the outcome of interest must be concerned with obesity-related cancers, including prostate, breast, colorectal, thyroid, renal, endometrial, pancreatic and esophageal cancers; (4) the study must report odds ratio (OR) or relative risk (RR), corresponding 95% confidence intervals (CI), mean and standard deviation (SD), or data to calculate these. Studies that did not refer to cancer, serum or plasma resistin, healthy controls, and that were conducted on animals, cells, or tissues were excluded. Two investigators (Wei Zheng and Wei-Jing Gong) reviewed all studies independently to identify and determine whether an individual study was eligible for inclusion in this meta-analysis. Any disagreement between the studies was resolved by consensus with a third reviewer (Zhao-Qian Liu).

Data extraction {#s4_3}
---------------

Data was extracted and assessed by two independent researchers (Li-Ming Tan and Wei-Jing Gong) using the Newcastle-Ottawa Scale (NOS). Disagreements were resolved by consensus. Data extracted from eligible studies included first author\'s last name, year of publication, country of origin, study design, BMI, age, cancer type, sample size, resistin detection assay, confounders adjusted in multivariate analysis, RR or OR with corresponding 95%CI for the risk of cancer incidence, mean and SD, or data to calculate them \[[@R34], [@R35]\].

Statistical analysis {#s4_4}
--------------------

Heterogeneity of effect size among studies was assessed by the Cochrane\'s *Q*-statistic test and *I^2^* test. If *P* \< 0.05 and *I^2^*\> 50%, a random effect model was used, otherwise, a fixed effect model was used \[[@R36], [@R37]\]. Sensitivity analysis was performed to assess the influence of a single study on the summary results. When heterogeneity was present, subgroup analysis, Galbraith plot and meta-regression analysis were used to detect the potential sources of heterogeneity \[[@R38], [@R39]\]. Funnel plots and Egger\'s test were carried out to estimate publication bias \[[@R40], [@R41]\]. Statistical analyses were performed using STATA version 12 (Stata Corp, College Station, TX, USA), and tests were two-sided with the criterion of statistical significance at *P* \< 0.05.
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